News
April 16, 2013 --- ugichem obtains another public funding
of € 850.000. Read more...March 15, 2013 --- ugichem to present at the Oligonucleotide Therapeutics Society Annual Meeting 2013 in Naples
(Oct. 6 - 8, 2013)February 28, 2013 --- ugichem
to present at the TIDES, Oligonucleotide & Peptide Therapeutics Conference
in Boston (May 12 - 15, 2013)
Welcome!
ugichem is developing proprietary new gene silencing therapeutics, the so-called Ugimers, which allow to overcome the shortcomings of established gene silencing technologies such as antisense oligonucleotides or siRNAs.
In contrast to the established gene silencing technologies, Ugimers are not derived from natural nucleic acids but exclusively designed towards function. As a result, organs and cells currently inaccessible with standard gene silencing technologies and even defined cellular compartments become targetable by Ugimers without the need for additional delivery tools.
ugichem's mission is to establish the Ugimers as a new class of top-grade medicines, initially focusing on indications requiring targeting of immune cells which are currently not functionally accessible by standard gene silencing compounds.
ugichem will further extend its Ugimer gene silencing technology into a therapeutic product platform dedicated to indications that are based on altered gene expression.